Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease
N Esters, S Vermeire, S Joossens, M Noman… - The American journal of …, 2002 - Elsevier
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab,
Remicade) is a new therapeutic approach for severe refractory luminal or fistulizing, Crohn's
disease (CD). However, up to 30% of patients do not respond to this treatment. So far, no
parameters predictive of response to anti-TNF have been identified. Our aim was to
determine whether serological markers ASCA (anti-Saccharomyces cerevisiae antibodies)
or pANCA (perinuclear antineutrophil cytoplasmic antibodies) could identify Crohn's patients …
Remicade) is a new therapeutic approach for severe refractory luminal or fistulizing, Crohn's
disease (CD). However, up to 30% of patients do not respond to this treatment. So far, no
parameters predictive of response to anti-TNF have been identified. Our aim was to
determine whether serological markers ASCA (anti-Saccharomyces cerevisiae antibodies)
or pANCA (perinuclear antineutrophil cytoplasmic antibodies) could identify Crohn's patients …